Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women
MH Schultze-Mosgau, B Schuett… - … Journal of Clinical …, 2017 - search.proquest.com
Objectives: Vilaprisan is a novel, potent, and highly selective progesterone receptor
modulator, which might offer a promising option for the treatment of uterine fibroids. Methods
and materials: In this randomized, placebo-controlled, parallel-group phase 1 study, the
pharmacokinetics and safety of vilaprisan were investigated in healthy postmenopausal
women. Subjects received a single oral dose of vilaprisan (1, 5, 15, or 30 mg) or placebo
and-after a wash-out period-daily doses of the same strength over 28 days. Safety …
modulator, which might offer a promising option for the treatment of uterine fibroids. Methods
and materials: In this randomized, placebo-controlled, parallel-group phase 1 study, the
pharmacokinetics and safety of vilaprisan were investigated in healthy postmenopausal
women. Subjects received a single oral dose of vilaprisan (1, 5, 15, or 30 mg) or placebo
and-after a wash-out period-daily doses of the same strength over 28 days. Safety …
Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in Chinese healthy postmenopausal women
H Liu, J Jiang, Z Chen, Y Zhang, J Li… - Clinical …, 2021 - Wiley Online Library
Vilaprisan is a novel selective progesterone receptor modulator for the long‐term treatment
of uterine fibroids and endometriosis. This study investigated the pharmacokinetics, safety,
and tolerability of vilaprisan in healthy Chinese postmenopausal women. Twelve
participants received multiple doses of vilaprisan once daily over 14 days as a 2‐mg tablet.
Plasma vilaprisan concentrations were determined using liquid chromatography–tandem
mass spectrometry. The main pharmacokinetic parameters of vilaprisan were assessed with …
of uterine fibroids and endometriosis. This study investigated the pharmacokinetics, safety,
and tolerability of vilaprisan in healthy Chinese postmenopausal women. Twelve
participants received multiple doses of vilaprisan once daily over 14 days as a 2‐mg tablet.
Plasma vilaprisan concentrations were determined using liquid chromatography–tandem
mass spectrometry. The main pharmacokinetic parameters of vilaprisan were assessed with …
以上显示的是最相近的搜索结果。 查看全部搜索结果